Laquinimod is a prescription medication used to treat relapsing-remitting multiple sclerosis (RRMS). It is a type of immunomodulator, which means it helps to modulate or regulate the body's immune system. Laquinimod works by reducing inflammation and slowing down the progression of MS. It is usually taken once daily, either as a tablet or an oral solution. Common side effects include headache, back pain, and nausea.
Laquinimod is an investigational drug currently undergoing clinical trials for its potential use in treating multiple sclerosis (MS) [1, 2]. Here's a breakdown of what we know so far:
- What is Laquinimod being studied for?
Laquinimod is primarily being investigated as a potential treatment for relapsing-remitting multiple sclerosis (RRMS), a common form of MS characterized by episodes of worsening symptoms (relapses) followed by periods of partial or complete recovery (remissions) [2].
- How Laquinimod might work:
The exact mechanism of action for Laquinimod is still under investigation, but it's believed to work in multiple ways:
- Immunomodulation: Laquinimod may modulate the immune system, potentially reducing inflammation that contributes to MS [2, 3].
- Neuroprotection: Laquinimod might also have neuroprotective effects, helping to protect nerve cells from damage in MS [3].
- Current status:
Laquinimod has shown promising results in clinical trials, demonstrating potential benefits in reducing relapse rates, slowing disease progression, and improving MRI outcomes in patients with RRMS [2, 3]. However, it has not yet received final approval from regulatory agencies for widespread use.
- Important things to consider:
- Laquinimod is not yet a commercially available medication.
- More research is needed to confirm its long-term safety and efficacy for MS treatment.
- If you have MS, it's important to consult with your doctor about currently approved treatment options.